Earnings call transcript: MedAdvisor Q4 2025 sees revenue dip, stock slides

MedAdvisor (ASX:MDR) reported a challenging Q4 2025, with U.S. revenue declining 34% year-over-year to A$10.1 million, leading to a revised FY25 revenue guidance of A$88 million and a projected EBITDA loss of A$6.5-A$7.3 million. This performance, despite a 52% surge in vaccine revenue, prompted a 2.53% stock price drop, compounding an 84% decline over the past year. Amid U.S. pharmacy market disruptions and program delays, MDR is restructuring operations, cutting costs, and plans to launch a new patient engagement platform in Q2 FY26. The company is also actively exploring a potential divestment of its U.S. business, aiming for 15% FY26 revenue growth from its U.S. base and near cash breakeven.

Analysis

MedAdvisor Ltd (ASX:MDR) reported significant operational and financial challenges in its Q4 2025 results, primarily driven by its U.S. business. A 34% year-over-year decline in U.S. revenue to $10.1 million AUD, attributed to program launch delays and broader pharmacy market disruption, forced a downward revision of FY25 guidance to $88 million AUD in revenue with a projected EBITDA loss between $6.5 million and $7.3 million AUD. This weakness overshadowed a 52% increase in vaccine-related revenue, highlighting a dependency on this segment. The company is responding with significant restructuring, including reducing its sales team and overhauling account management, while holding $16 million AUD in cash post-divestment of its ANZ business. Critically, the board is exploring a potential divestment of the entire U.S. business. The outlook for FY26 projects 15% revenue growth, but this is based on the troubled U.S. revenue base and notably includes $4.8 million in revenue deferred from FY25, suggesting underlying growth may be weaker. The launch of a next-generation patient engagement platform in Q2 FY26 and a target of 10% lower operating expenses are presented as key catalysts for a turnaround, though the company remains close to, but not yet at, cash breakeven.

Key Decisions for Investors

• Investors should closely monitor the ongoing strategic review, as the potential divestment of the U.S. business is a primary catalyst that could fundamentally alter the company's structure and valuation.
• Scrutinize the quality of the projected 15% revenue growth in FY26, specifically distinguishing between the impact of the one-off $4.8 million deferred revenue and new, organic growth from the restructured commercial team.
• Assess the company's ability to achieve its targeted 10% reduction in U.S. operating expenses and reach cash breakeven, as execution on cost control is critical given the revenue headwinds and ongoing EBITDA losses.
• While the stock has declined over 84% and may appear undervalued, the combination of market disruption, operational restructuring, and strategic uncertainty necessitates a high tolerance for risk.